Each of the NNZ-2591 trials had to recruit and dose older patients first and then receive approval to proceed to dose the next younger group, some had three age groups. It was always expected to take a reasonable length to go through the cycle several times.
Ann: Neuren commences Phase 2 trial of NNZ-2591 in Angelman, page-20
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.03 |
Change
0.700(4.29%) |
Mkt cap ! $2.139B | |||
| Open | High | Low | Value | Volume |
| $16.49 | $17.21 | $16.44 | $11.40M | 677.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4624 | $17.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.05 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |